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Background: Research indicates that a large proportion of patients using medication targeting
obstructive lung disease have no history of spirometry testing.
Objective: To investigate the use of spirometry when initiating pulmonary medication target-
ing obstructive lung disease and to explore possible patient characteristics associated with
undergoing spirometry.
Methods: Population-based cohort study. Three Danish National registers were linked enabling
a retrieval of data on all primary and secondary healthcare services provided in the time period
2007e2010.
Results: In 2008 a total of 40,969 patients were registered as first time users of pulmonary
medication targeting obstructive lung disease. The mean age of the study cohort was 55.6
yrs (SD 18.7). Spirometry test had been performed in 20,262 (49.5%) of the study cohort in
the period from 6 months before to 12 months after their first prescription. Just above one
third of the cohort, 14,275 (34.8%), had undergone spirometry in the two-month period close
to redemption of their first prescription. Women and patients in the oldest age categories were
less likely to have spirometry performed.
Conclusions: Many patients initiate medication targeting obstructive pulmonary disease
without having airway obstruction confirmed through spirometry. Only one third of the study
cohort had a spirometry performed when initiating medication and half had still not undergone
spirometry after a year. There should be an increased focus on confirming airway obstruction
when initiating medication.
ª 2012 Elsevier Ltd. All rights reserved.50 4244.
.sdu.dk (M.M. Koefoed).
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Spirometry is recommended as the gold standard for con-
firming obstructive lung disease and is a cornerstone in diag-
nosing thediseases asthmaandchronic obstructivepulmonary
disease (COPD).1,2 Initiating medication for obstructive lung
disease without spirometry entails the risk that patients use
this medication without evidence of airway obstruction.
Neither clinical examination nor history taking can diagnose
COPD adequately or distinguish it from asthma or other
illnesses also giving respiratory symptoms.3e5 Although
medication relieves symptoms, reduces risk of exacerbations
and improves quality of life,6,7 it is not without risk8,9 and
spirometry should beperformed toensurecorrect diagnosis.10
However, studies have shown that a large proportion of
patients diagnosed with COPD or asthma have no history of
spirometry testing.11e14 Further, it has been indicated that
many patients are prescribed medication for obstructive lung
disease without a relevant diagnosis of COPD or asthma
registered.15,16 We found no studies estimating the use of
spirometry when initiating medication targeting obstructive
lung disease. Some studies have shown gender differences in
disease management17 and age has also been identified as
a factor influencing whether spirometry is performed.18 The
aim of this study was therefore to assess to what extent
spirometry is conducted when initiating medication targeting
obstructive lung disease, and to explore possible patient
characteristics associated with undergoing spirometry.Methods
This population-based cohort study links three national
registers: the Danish National Prescription Register, the
Danish National Patient Register and the Danish National
Health Service Register. These registries cover the entire
population of Denmark and contain information on all
healthcare services provided. All Danish citizens are
assigned a unique civil registration number (CPR), which
enables accurate linkage between these registries.19
Denmark has a tax-funded public healthcare system,
providing free access to general practice and hospital care.
More than 98% of Danish citizens are registered with a GP
who act as a gatekeeper to the rest of the healthcare
system by carrying out initial diagnostic investigations and
referring patients to secondary care if necessary.Figure 1 Sampling algorithm.The Danish national registries
The Danish National Health Service Register contains
information on all services provided in primary health care.
Each registration includes the patients CPR, identification
code for type of activity performed, e.g. spirometry,
identification code for the primary healthcare clinic
providing the health service and the week for reimburse-
ment of the healthcare service.20
The Danish National Patient Register records all hospital
admissions, contacts to emergency departments and
contacts to outpatient clinics. Each record includes the
patients CPR, the date of admission, data on the hospital
and diagnostic and procedure codes including spirometry.21The Danish National Prescription Register records all
prescribedmedications that are redeemed. Each prescription
record includes the patient’s CPR, identification code of the
prescriber, date of purchase, the brand name, anatomical
therapeutic chemical system code (ATC), dose unit and
quantity. Thedaily doseand indication arenot recorded in the
database.22 Allmedication targeting obstructive lung disease,
defined as all medications within the ATC code R03, requires
a prescription and registration is therefore complete. Medi-
cation with ATC code R03 include: Beta-2-agonists, anticho-
linergic drugs, inhaled corticosteroids, montelukast,
theophylline, sodium cromoglycate, and omalizumab.
Sampling algorithm: identification of first time users
of medication targeting obstructive lung disease
The Danish National Prescription Register was used to iden-
tify all adults who were first time users of medication tar-
geting obstructive lung disease in 2008. Selection criteria
were as follows: 1) All patients redeeming drugs with ATC
code R03 in 2008 were identified, 2) patients under 18 years
of age on 1 January 2008were excluded, and 3) patients with
records of previously redeemed prescriptions with ATC code
R03 in the prescription database (1995e2007) were
excluded. Sampling algorithm is demonstrated in Fig. 1.The
date the first prescription was redeemed was defined as the
index date. Patients were defined as having repeated
redemption ofmedication for obstructive lungdisease if they
redeemed more than one prescription of medication for
obstructive lung disease (ATC R03) within a one-year interval
and the interval between the two prescriptions exceeded 30
days. Number of therapies redeemed in the first year was
assessed for each patient within the threemain categories of
R03 medication: Beta-2-agonists, anticholinergics and
inhaled corticosteroids. Other medications within the ATC
R03 category were rarely prescribed and were therefore
excluded from analyses.
Spirometry
Records of spirometric procedures provided in the time
period 2007e2010 were extracted from the Danish National
Table 1 Characteristics of first time users of medication
targeting obstructive lung disease. Total number 40,969.
Characteristics N %
Gender
Male 19,083 46.6
Female 21,886 53.3
Age
Male 56.3 yrs
(SD 18.1)
Female 55.0 yrs
(SD 19.1)
Repeated redemption
Yes 15,279 37.3
No 25,690 62.7
Number of pulmonary medication initiated
Monotherapy 24,760 60.4
Only beta agonist 17,709
Only anticholinergics 1359
Only inhaled steroids 4764
Others 928
Two therapies 13,757 33.6
Beta
agonist þ anticholinergics
2123
Beta
agonist þ inhaled steroids
11,535
Inhaled
steroids þ anticholinergics
99
Three therapies
Beta agonist þ anticholinergics
þ inhaled steroids
2452 6.0
Lack of spirometry use in Danish patients 1745Health Service Register and the Danish National Patient
Register. Patients were categorized as having the spirometry
performed in general practice, other primary care clinics or
hospital setting. For each patient we assessed if spirometry
was conducted in an 18-month period from 6 months before
to 12months after the index date. The shortest time interval
between the index date and spirometry was extracted.
Further, we assessed the proportion of patients who had
spirometry performed in a two-monthperiod fromonemonth
before to one month after the index date.
Statistics
Patient characteristics are reported using means and stan-
dard deviations (SD) to describe continuous variables and
percentages (%) to describe categorical variables. Logistic
regression models were used to calculate unadjusted and
adjusted odds ratios (ORs) with 95% CIs for the associations
between patient characteristics and spirometry in the 18-
month period. The patient characteristics included were:
gender, age, number of types of pulmonary medication
initiated 12 months preceding the index date and if
patients had redeemed prescriptions repeatedly. P-
values < 0.05 were considered statistically significant. All
statistical analyses were carried out using STATA 11 (STA-
TACorp, College Station, TX, USA).
Ethics
This project is register-based and according to “The Act on
Research Ethics Review of Health Research Projects in
Denmark” only questionnaire surveys and medical database
research projects involving human biological material are
required to be notified to the research ethics committee.
The research ethics committee has, therefore, not been
contacted. The study was approved by the Danish Data
Protection Agency, J.nr. 2011-41-5798.
Results
Cohort characteristics
A total of 40,969 patients >18 years were identified as first
time users of medication targeting obstructive lung disease in
2008 (Fig. 1). The mean age of the study cohort of first time
users was 55.6 years (SD 18.7). There was a slight predomi-
nance of women (53.3% vs. 46.6%), and they were slightly
younger (55.0 yrs (SD 19.1) vs. 56.3 yrs (SD 18.1)), (Table 1).
Theagedistribution is shown inFig. 2.A total of 24,760 (60.4%)
used only one type of pulmonary medication within the first
year. Just about one third of the cohort 13,757 (33.6%) used
two types of pulmonary medication. The remaining 2452
(6.0%) of the cohort used all three types of pulmonary medi-
cation within the first year. A total of 15,279 (37.3%) had
redeemed medication prescriptions repeatedly, Table 1.
Spirometry
The proportion of patients having undergone at least one
spirometry in the period from 6 months before to 12 monthsafter their first prescription is shown in Table 2. A total of
20,262 (49.5%) of the study cohort had spirometry per-
formed, whereas only 14,275 of the study cohort (34.8%)
had a spirometry performed within the two-month period
(data not shown). Among patients on monotherapy only
37.3% had spirometry performed, this increased to 65.7%
among patients using two therapies and to 81.2% among
patients using three therapies. In patients with repeated
redemption of medication for obstructive lung disease,
69.9% had spirometry performed.
The time distribution from the index date to spirometry
is shown in Fig. 3. The figure also demonstrates in which
setting the spirometry test was performed; the large
majority were conducted in primary care.Patient factors associated with spirometry
Table 3 shows crude and adjusted odds ratios for associa-
tions between spirometry testing and age, gender, number
of pulmonary medication initiated and repeated redemp-
tion. Patients in age categories 28e47 years and above 68
years had statistically significantly lower chance of having
spirometry performed in the 18-month period. For age
category 78e87 years there was an adjusted odds ratio 0.51
(95% CI 0.46e0.56) compared with the youngest age cate-
gory (18e27 years) and for age category þ88 years an
adjusted OR of 0.15 (95% CI 0.12e0.18) for having
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Figure 2 Age distribution of first time users of medication targeted obstructive lung disease. Total number of patients N: 40,969.
1746 M.M. Koefoed et al.spirometry performed. Women were less likely to have
spirometry performed with an adjusted OR of 0.86 (95% CI
0.82e0.90). There was an increasing chance of undergoing
spirometry with increasing number of pulmonary medica-
tion initiated within the first year and with repeated
redemption.
Discussion
This study captures all first time users of obstructive
pulmonary medication in Denmark in 2008. Only one third
of these patients had spirometry performed when initiating
medication and approximately half did still not have
spirometry performed 12 months after initiating medica-
tion. Women and patients in the oldest age categories were
less likely to have spirometry performed.Table 2 The proportion of patients having received at
least one spirometry in the period from 6 months before to
12 months after their first prescription according to patient
characteristics.
Characteristics Spirometry
recorded N (%)
Total N
All 20,262 (49.5) 40,969
Gender
Male 9970 (52.2) 19,083
Female 10,292 (47.0) 21,886
Age categories
18e27 2123 (47.6) 4461
28e37 2495 (41.1) 6072
38e47 2847 (46.1) 6179
48e57 3307 (51.3) 6441
58e67 4486 (56.7) 7907
68e77 3333 (57.6) 5791
78e87 1527 (45.5) 3357
88e 144 (18.9) 761
Repeated redemption
Yes 10,674 (69.9) 15,279
No 9588 (37.3) 25,690
Number of pulmonary medication initiated
Monotherapy 9236 (37.3) 24,760
Two therapies 9036 (65.7) 13,757
Three therapies 1990 (81.2) 2452A major strength is the population-based design
reflecting an entire population’s drug and health care
utilization. Prescription data are complete; all redeemed
prescriptions are registered, including all medication for
obstructive lung disease, thereby capturing all first time
users of this medication. Furthermore, our study comprises
the entire healthcare system; all spirometry measurements
from primary and secondary health care are assessed. The
study may have some methodological limitations though;
the Danish National Prescription Registry contains only
redeemed prescriptions and it is therefore not possible to
identify patients who do not redeem prescribed medication
and they will be misclassified. However, we do not consider
this misclassification to be a major problem as primary non-
compliance is considered small.23 The registry also has no
data on the dose or indication for the drug, making it
impossible for us to differentiate between different
obstructive pulmonary diseases. As we aimed to assess
whether spirometry is performed to confirm obstruction
when medication targeting obstructive lung diseases is
prescribed, we did not find diagnosis important for this
study. However, although confirming obstruction through
spirometry is mandatory in diagnosing COPD and recom-
mended in asthma, repeated peak expiratory flow
measurements (PEF) confirming variation of obstruction can
be used as an alternative diagnostic strategy in young
patients where COPD is unlikely. In Denmark all GP’s have
access to spirometry, making this preferred diagnostic
strategy easy to perform. Although it cannot be excluded
that PEF measurements to a minor extent might have
substituted spirometry in the youngest age categories, PEF
cannot be applied to the vast majority of the cohort and
therefore does not significantly influence our findings.
Identification of spirometric procedures depends on the
comprehensiveness of the Danish National Health Service
Register and the Danish National Patient Register. There are
no studies assessing the consistency of coding of spiro-
metric procedures in these two registries. An under-
reporting to these registers would lead to an
underestimation of spirometry testing. Reporting of
spirometry in primary health care is assumed to be high,
because this is prerequisite for reimbursement. In
secondary care coding is done routinely, it increases
payment and is therefore also considered consistent.
Although caution must be taken when interpreting data, we
do not consider underreporting to be a significant problem.
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Figure 3 Time from the first prescription of medication
targeting obstructive lung disease to spirometry*. *The shortest
time interval between the index date and spirometry is
illustrated.
Lack of spirometry use in Danish patients 1747We were unable to find published studies assessing the
utilization of spirometry in patients initiating medication
targeting obstructive lung disease. The PLATINO study, by
Montes et al.,16 estimated the prevalence of respiratory
medication use and spirometry utilization among these
medicationusers infiveLatinAmerican cities.Of thepatients
reporting use of any bronchodilator or corticosteroid in the
previous 12 months, only 37.5% reported a history of
spirometry testing. That study demonstrated a lower
spirometry testing among medication users than the one
found in our study. This difference could de due to study
design and local differences. An interesting finding was that
70% of the patients receiving bronchodilators and/or corti-
costeroids had no airway obstruction when tested with
spirometry; emphasizing the importance of confirmation of
obstruction in patients using medication targetingTable 3 Logistic regression analysis to assess if there is an assoc
received, repeated redemption and spirometry.
N Crude OR
Gender
Male 19,083 1
Female 21,886 0.81*
Age category
18e27 4461 1
28e37 6072 0.77*
38e47 6179 0.94
48e57 6441 1.16*
58e67 7907 1.44*
68e77 5791 1.49*
78e87 3357 0.92
88e 761 0.26*
N. of pulmonary therapies initiated
1 24,760 1
2 13,757 3.22*
3 2452 7.24*
Repeated redemption
No 25,690
Yes 15,279 3.89*
*P-value < 0.05.obstructive lung disease. Joish et al. demonstrated that
patients diagnosed with COPD were using medication before
this diagnosis was registered and the median time from
prescription to diagnosis was approximately one year.15
These findings facilitate our hypothesis that patients use
medication without a relevant diagnosis and spirometry
testing is underused among medication users. Many studies
have shownanunderutilization of spirometry amongpatients
with a diagnosis of asthma or COPD.11e14,18,24 A Swedish
study conductedbyArne et al. demonstrated that spirometry
was only documented in 59% of the patients in connection
with a diagnosis of COPD.13 Our study confirms that this
underutilization of spirometry is also present among patients
initiating pulmonary medication targeting these illnesses.
Our study explored a possible association between
spirometry and the patient’s age and gender. We have not
found any other studies comparing gender differences in
spirometry utilization among pulmonary medication users.
Three studies have compared gender differences in
spirometry utilization among COPD patients; Watson
et al.17 found an underuse of spirometry testing among
women (OR of 0.84, 95% C.I. 0.72e0.98) in concordance
with Arne et al.,13 Han et al.18 found the opposite. Although
our study is not readily comparable with these studies we
conclude that gender difference still persists. Patients in
our study had a lower OR of having spirometry performed in
age categories 28e47 years and in patients >68 years. The
OR was lowest in age categories 78e87 years and above 88
years, in concordance with Han et al.’s18 findings and it is
noteworthy that both studies found a clear underuse in the
oldest patients. There is no obvious explanation, but
a similar finding has been seen in management of ischemic
heart disease.25 Correct diagnosis is essential in the oldest
age groups, as increasing comorbidity increases the risk of
misdiagnosis. We found that increasing number of therapiesiation between gender, age, number of pulmonary medication
95% CI Adjusted OR 95% CI
e e
0.78e0.84 0.86* 0.82e0.90
e e
0.71e0.83 0.73* 0.67e0.79
0.87e1.02 0.85* 0.79e0.92
1.08e1.25 0.96 0.88e1.03
1.34e1,55 1.02 0.94e1.11
1.38e1.62 0.90* 0.83e0.98
0.84e1.01 0.51* 0.46e0.56
0.21e0.31 0.15* 0.12e0.18
e e
3.08e3.36 2.27* 2.16e2.38
6.52e8.04 3.93* 3.51e4.40
e
3.73e4.06 2.65* 2.52e2.78
1748 M.M. Koefoed et al.initiated and repeated redemption both significantly
increased the chance of undergoing spirometry. This asso-
ciation is not surprising, as they could both be a proxy for
disease severity. Only one third of the patients on mono-
therapy had spirometry performed, this increased to just
two thirds in patients initiating two therapies, and even in
patients initiating three therapies there is still one out of
five who did not have spirometry performed.
This study demonstrates that a high percentage of patients
treated with medication targeting obstructive pulmonary
diseases do not undergo spirometry. We found a clear under-
use of spirometry in the oldest age categories and among
women.Whyprescribing is oftendonewithout confirmationof
obstruction through spirometry testing remains unanswered,
but efforts to increase spirometry utilization must be made.
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